Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1359 ARTÍCULOS , VIENDO DEL 1126 AL 1140

Searching for novel biomarkers using high resolution diffusion tensor imaging

Yassa MA.

J Alzheimers Dis. 2011;26 Suppl 3(Suppl 3):297-305. doi: 10.3233/JAD-2011-0005.

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

Reiman EM; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S44-7. doi: 10.1016/j.neurobiolaging.2011.09.007. Epub 2011 Oct 7.

Clinical trial methodologies for disease-modifying therapeutic approaches

Aisen PS.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S64-6. doi: 10.1016/j.neurobiolaging.2011.09.008. Epub 2011 Oct 8.

Aβ-degrading enzymes: potential for treatment of Alzheimer disease

Miners JS, Barua N, Kehoe PG, Gill S, Love S.

J Neuropathol Exp Neurol. 2011 Nov;70(11):944-59. doi: 10.1097/NEN.0b013e3182345e46.

Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits

Di Domenico F, Coccia R, Butterfield DA, Perluigi M.

Biochim Biophys Acta. 2011 Dec;1814(12):1785-95. doi: 10.1016/j.bbapap.2011.10.001. Epub 2011 Oct 12.

Challenges in the development of companion diagnostics for neuropsychiatric disorders

Nikolcheva T, Jäger S, Bush TA, Vargas G.

Expert Rev Mol Diagn. 2011 Nov;11(8):829-37. doi: 10.1586/erm.11.67.

The role of reelin gene polymorphisms in the pathogenesis of Alzheimer's disease in a Greek population

Antoniades D, Katopodi T, Pappa S, Lampropoulos A, Konsta V, Frydas E, Mpalogiannis S, Hatzistilianou M.

J Biol Regul Homeost Agents. 2011 Jul-Sep;25(3):351-8.

Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions

Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RD.

Mol Aspects Med. 2011 Aug;32(4-6):247-57. doi: 10.1016/j.mam.2011.10.005. Epub 2011 Oct 21.

Risk-takers wanted

Nat Med. 2011 Nov 7;17(11):1321. doi: 10.1038/nm.2573.

Evolution of the diagnostic criteria for degenerative and cognitive disorders

Lopez OL, McDade E, Riverol M, Becker JT.

Curr Opin Neurol. 2011 Dec;24(6):532-41. doi: 10.1097/WCO.0b013e32834cd45b.

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies

Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM.

Expert Rev Neurother. 2011 Dec;11(12):1783-93. doi: 10.1586/ern.11.168.

Alzheimer disease biomarkers are associated with body mass index

Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Nov 22;77(21):1913-20. doi: 10.1212/WNL.0b013e318238eec1.

The future of Alzheimer's disease: the next 10 years

Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F; German Task Force on Alzheimer's Disease (GTF-AD).

Prog Neurobiol. 2011 Dec;95(4):718-28. doi: 10.1016/j.pneurobio.2011.11.008. Epub 2011 Nov 22.

Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants

Mayeux R, Schupf N.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S10-9. doi: 10.1016/j.neurobiolaging.2011.09.004.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias